Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

Michael G Benatar, Donald B. Sanders, Gil I. Wolfe, Michael P. McDermott, Rabi Tawil

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume1275
Issue number1
DOIs
StatePublished - Dec 1 2012

Fingerprint

Prednisone
Cholinesterase Inhibitors
Muscle
Therapeutics
Placebos
Muscles
Efficacy

Keywords

  • Clinical trial
  • Evidence-based medicine
  • Ocular myasthenia
  • Steroids

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. / Benatar, Michael G; Sanders, Donald B.; Wolfe, Gil I.; McDermott, Michael P.; Tawil, Rabi.

In: Annals of the New York Academy of Sciences, Vol. 1275, No. 1, 01.12.2012, p. 17-22.

Research output: Contribution to journalArticle

Benatar, Michael G ; Sanders, Donald B. ; Wolfe, Gil I. ; McDermott, Michael P. ; Tawil, Rabi. / Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. In: Annals of the New York Academy of Sciences. 2012 ; Vol. 1275, No. 1. pp. 17-22.
@article{f4e869d3aacd41dbb2b9a520af5b5db6,
title = "Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial",
abstract = "Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.",
keywords = "Clinical trial, Evidence-based medicine, Ocular myasthenia, Steroids",
author = "Benatar, {Michael G} and Sanders, {Donald B.} and Wolfe, {Gil I.} and McDermott, {Michael P.} and Rabi Tawil",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/j.1749-6632.2012.06780.x",
language = "English",
volume = "1275",
pages = "17--22",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

AU - Benatar, Michael G

AU - Sanders, Donald B.

AU - Wolfe, Gil I.

AU - McDermott, Michael P.

AU - Tawil, Rabi

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

AB - Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

KW - Clinical trial

KW - Evidence-based medicine

KW - Ocular myasthenia

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84871591629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871591629&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2012.06780.x

DO - 10.1111/j.1749-6632.2012.06780.x

M3 - Article

C2 - 23278573

AN - SCOPUS:84871591629

VL - 1275

SP - 17

EP - 22

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -